CD4+ T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation

被引：67

作者：

Sharkey, MS ^{[1
]}

Lizée, G ^{[1
]}

Gonzales, MI ^{[1
]}

Patel, S ^{[1
]}

Topalian, SL ^{[1
]}

机构：

[1] NCI, Surg Branch, NIH, Canc Res Ctr, Bethesda, MD 20892 USA

来源：

CANCER RESEARCH | 2004年 / 64卷 / 05期

关键词：

D O I：

10.1158/0008-5472.CAN-03-3231

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed frequently in melanomas and may play an important role in the biology of this disease. A 29-mer B-Raf peptide incorporating the V599E mutation was used for in vitro stimulation of lymphocytes derived from melanoma patients, generating MHC class II-restricted CD4(+) T cells specific for this peptide as well as for melanoma cells expressing B-Raf V599E. Mutated B-Raf exemplifies targets that may be ideal for immunotherapy.

引用

页码：1595 / 1599

页数：5

共 16 条

[1] DEVELOPMENT OF HIGH POTENCY UNIVERSAL DR-RESTRICTED HELPER EPITOPES BY MODIFICATION OF HIGH-AFFINITY DR-BLOCKING PEPTIDES [J].

ALEXANDER, J ;

SIDNEY, J ;

SOUTHWOOD, S ;

RUPPERT, J ;

OSEROFF, C ;

MAEWAL, A ;

SNOKE, K ;

SERRA, HM ;

KUBO, RT ;

SETTE, A ;

GREY, HM .

IMMUNITY, 1994, 1 (09) :751-761

[2]

Brose MS, 2002, CANCER RES, V62, P6997

[3] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[4]

Dong JL, 2003, CANCER RES, V63, P3883

[5]

GJERTSON DW, 1998, HLA 1998

[6]

Gorden A, 2003, CANCER RES, V63, P3955

[7]

Hingorani SR, 2003, CANCER RES, V63, P5198

[8] Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy [J].

Nimmerjahn, F ;

Milosevic, S ;

Behrends, U ;

Jaffee, EM ;

Pardoll, DM ;

Bornkamm, GW ;

Mautner, J .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (05) :1250-1259

[9] Biochemical identification of a mutated human melanoma antigen recognized by CD4+ T cells [J].

Pieper, R ;

Christian, RE ;

Gonzales, MI ;

Nishimura, MI ;

Gupta, G ;

Settlage, RE ;

Shabanowitz, J ;

Rosenberg, SA ;

Hunt, DF ;

Topalian, SL .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (05) :757-765

[10] High frequency of BRAF mutations in nevi [J].

Pollock, PM ;

Harper, UL ;

Hansen, KS ;

Yudt, LM ;

Stark, M ;

Robbins, CM ;

Moses, TY ;

Hostetter, G ;

Wagner, U ;

Kakareka, J ;

Salem, G ;

Pohida, T ;

Heenan, P ;

Duray, P ;

Kallioniemi, O ;

Hayward, NK ;

Trent, JM ;

Meltzer, PS .

NATURE GENETICS, 2003, 33 (01) :19-20

← 1 2 →